NVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SPPI

Group 1 - The core issue involves a securities class action lawsuit against Spectrum Pharmaceuticals, alleging securities fraud or unlawful business practices by the company and certain officers or directors [2][3] - The lawsuit specifically relates to misleading statements made by Spectrum regarding its Pinnacle Study, a clinical trial for the drug poziotinib, aimed at treating certain lung cancer patients [3] - Investors have until September 24, 2025, to apply for the position of Lead Plaintiff in the class action if they purchased or acquired Spectrum securities during the Class Period [3] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has a long-standing reputation, having been founded over 85 years ago by Abraham L. Pomerantz, who is known as a pioneer in the field of securities class actions [4]